12:19 PM
Nov 27, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Acute myelogenous leukemia (AML)

Cell culture and mouse studies identified an indole-dihydropyrazine-based MCL1 inhibitor that could help treat AML in combination with Venclyxto venetoclax. In mononuclear bone marrow cells from six AML patients who were refractory to or relapsed after treatment with the BCL-2 inhibitor Venclyxto, a previously reported MCL1 inhibitor plus Venclyxto decreased viability...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >